

Reference number(s)
1885-A

SPECIALTY GUIDELINE MANAGEMENT

ORKAMBI (lumacaftor/ivacaftor)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Treatment of cystic fibrosis (CF) in patients age 2 years and older who are homozygous for the *F508del* mutation in the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene. If the patients genotype is unknown, an FDA cleared CF mutation test should be used to detect the presence of the *F508del* mutation on both alleles of the *CFTR* gene.

Limitation of use: The efficacy and safety of Orkambi have not been established in patients with CF other than those homozygous for the *F508del* mutation.

All other indications are considered experimental/investigational and are not a covered benefit.

II. REQUIRED DOCUMENTATION

The following information is necessary to initiate the prior authorization review: genetic testing report confirming the presence of the appropriate *CFTR* gene mutation.

III. CRITERIA FOR INITIAL APPROVAL

Cystic Fibrosis

Indefinite authorization may be granted for treatment of cystic fibrosis when all of the following criteria are met:

- A. Genetic testing was conducted to detect a mutation in the *CFTR* gene.
- B. The member is positive for the *F508del* mutation on both alleles of the *CFTR* gene.
- C. The member is at least 2 years of age.
- D. Orkambi will not be used in combination with Kalydeco or Symdeko.

IV. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

V. REFERENCES

1. Orkambi [package insert]. Boston, MA: Vertex Pharmaceuticals Inc.; August 2018.

Reference number(s)
1885-A